CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone that primarily functions as an analogue of growth hormone releasing hormone (GHRH). It was invented by the Canadian biotechnology company ConjuChem. One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thereby increasing its half-life and therapeutic window. This is achieved by using protecting groups around the amino acids GHRH, which are usually susceptible to enzymatic degradation. The aim of the drug was to treat visceral fat deposits in obese AIDS patients, as elevated levels of exogenous HGH are believed to increase lipolysis (fat loss).
1 vial + 1 amp solvent (2mg/vial)
Single dose vial